Biomarin Pharmaceutical Inc. ((BMRN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioMarin Pharmaceutical Inc. is conducting a Phase 2 basket study titled ‘A Phase 2, Randomized, Human Growth Hormone-Controlled, Multicenter, Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With an Inadequate Response to Human Growth Hormone.’ The study aims to assess the efficacy of vosoritide, a modified recombinant human C-type natriuretic peptide, in improving growth in children with these conditions compared to human growth hormone (hGH) treatment.
The study tests three doses of vosoritide, administered as injections, against hGH. The goal is to evaluate growth improvement over six months, with long-term safety and efficacy assessed up to final adult height.
This interventional study is randomized with a parallel assignment, and employs triple masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide a new therapeutic option for children who do not respond adequately to hGH.
The study began on October 30, 2024, with primary completion expected soon. The latest update was submitted on August 1, 2025. These dates are crucial for tracking progress and anticipating results.
For investors, this study could influence BioMarin’s stock performance, especially if vosoritide proves effective, potentially positioning the company ahead of competitors in pediatric growth disorder treatments. The ongoing recruitment and updates suggest active progress.
The study is ongoing, with further details available on the ClinicalTrials portal.